Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion type Assertion NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_head.
- NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion description "[The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has produced remarkable clinical response in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_provenance.
- NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion evidence source_evidence_literature NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_provenance.
- NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion SIO_000772 25189416 NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_provenance.
- NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion wasDerivedFrom befree-2016 NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_provenance.
- NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_assertion wasGeneratedBy ECO_0000203 NP1216943.RAueVoQ1MyAoyD2gfiU4byKUBrqM3rTD34cpLH2VXfBgI130_provenance.